These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 18163485)

  • 21. PRTX-100 and methotrexate in patients with active rheumatoid arthritis: A Phase Ib randomized, double-blind, placebo-controlled, dose-escalation study.
    Bernton E; Gannon W; Kramer W; Kranz E
    Clin Pharmacol Drug Dev; 2014 Nov; 3(6):477-86. PubMed ID: 27129122
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nonclinical safety, pharmacokinetics, and pharmacodynamics of atacicept.
    Carbonatto M; Yu P; Bertolino M; Vigna E; Steidler S; Fava L; Daghero C; Roattino B; Onidi M; Ardizzone M; Peano S; Visich J; Janszen D; Dillon S; Ponce R
    Toxicol Sci; 2008 Sep; 105(1):200-10. PubMed ID: 18522929
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial.
    Kappos L; Hartung HP; Freedman MS; Boyko A; Radü EW; Mikol DD; Lamarine M; Hyvert Y; Freudensprung U; Plitz T; van Beek J;
    Lancet Neurol; 2014 Apr; 13(4):353-63. PubMed ID: 24613349
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Subcutaneously administered ofatumumab in rheumatoid arthritis: a phase I/II study of safety, tolerability, pharmacokinetics, and pharmacodynamics.
    Kurrasch R; Brown JC; Chu M; Craigen J; Overend P; Patel B; Wolfe S; Chang DJ
    J Rheumatol; 2013 Jul; 40(7):1089-96. PubMed ID: 23729801
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multicenter, randomized, double-blind, controlled trial of treatment of active rheumatoid arthritis with T-614 compared with methotrexate.
    Lu LJ; Bao CD; Dai M; Teng JL; Fan W; Du F; Yang NP; Zhao YH; Chen ZW; Xu JH; He PG; Wu HX; Tao Y; Zhang MJ; Han XH; Li XF; Gu JR; Li JH; Yu H
    Arthritis Rheum; 2009 Jul; 61(7):979-87. PubMed ID: 19565542
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis.
    Cambridge G; Leandro MJ; Edwards JC; Ehrenstein MR; Salden M; Bodman-Smith M; Webster AD
    Arthritis Rheum; 2003 Aug; 48(8):2146-54. PubMed ID: 12905467
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial).
    Isenberg D; Gordon C; Licu D; Copt S; Rossi CP; Wofsy D
    Ann Rheum Dis; 2015 Nov; 74(11):2006-15. PubMed ID: 24951103
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein, Ro 45-2081 (lenercept): results of a dose-finding study in rheumatoid arthritis.
    Furst DE; Weisman M; Paulus HE; Bulpitt K; Weinblatt M; Polisson R; Zaug M; Kneer J; Van der Auwera P; Stevens RM
    J Rheumatol; 2003 Oct; 30(10):2123-6. PubMed ID: 14528504
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial.
    Cohen S; Hurd E; Cush J; Schiff M; Weinblatt ME; Moreland LW; Kremer J; Bear MB; Rich WJ; McCabe D
    Arthritis Rheum; 2002 Mar; 46(3):614-24. PubMed ID: 11920396
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors.
    Genovese MC; Greenwald M; Cho CS; Berman A; Jin L; Cameron GS; Benichou O; Xie L; Braun D; Berclaz PY; Banerjee S
    Arthritis Rheumatol; 2014 Jul; 66(7):1693-704. PubMed ID: 24623718
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus: Results of a Twenty-Four-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase IIb Study.
    Merrill JT; Wallace DJ; Wax S; Kao A; Fraser PA; Chang P; Isenberg D;
    Arthritis Rheumatol; 2018 Feb; 70(2):266-276. PubMed ID: 29073347
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial.
    Ginzler EM; Wax S; Rajeswaran A; Copt S; Hillson J; Ramos E; Singer NG
    Arthritis Res Ther; 2012 Feb; 14(1):R33. PubMed ID: 22325903
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Week-112 Efficacy and Safety Results of the Open-Label Long-Term Extension of a Phase III, Double-Blind, Randomized, Placebo-Controlled Trial.
    Bingham CO; Mendelsohn AM; Kim L; Xu Z; Leu J; Han C; Lo KH; Westhovens R; Weinblatt ME;
    Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1627-36. PubMed ID: 25623393
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial.
    Keystone EC; Schiff MH; Kremer JM; Kafka S; Lovy M; DeVries T; Burge DJ
    Arthritis Rheum; 2004 Feb; 50(2):353-63. PubMed ID: 14872476
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial.
    Choy EH; Isenberg DA; Garrood T; Farrow S; Ioannou Y; Bird H; Cheung N; Williams B; Hazleman B; Price R; Yoshizaki K; Nishimoto N; Kishimoto T; Panayi GS
    Arthritis Rheum; 2002 Dec; 46(12):3143-50. PubMed ID: 12483717
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study.
    Aletaha D; Bingham CO; Tanaka Y; Agarwal P; Kurrasch R; Tak PP; Popik S
    Lancet; 2017 Mar; 389(10075):1206-1217. PubMed ID: 28215362
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety, tolerability, pharmacokinetics, and pharmacodynamics of anti-TWEAK monoclonal antibody in patients with rheumatoid arthritis.
    Wisniacki N; Amaravadi L; Galluppi GR; Zheng TS; Zhang R; Kong J; Burkly LC
    Clin Ther; 2013 Aug; 35(8):1137-49. PubMed ID: 23928094
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy.
    Kavanaugh A; St Clair EW; McCune WJ; Braakman T; Lipsky P
    J Rheumatol; 2000 Apr; 27(4):841-50. PubMed ID: 10782805
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of the monoclonal antibody ASK8007 blocking osteopontin in patients with rheumatoid arthritis: a randomised, placebo controlled, proof-of-concept study.
    Boumans MJ; Houbiers JG; Verschueren P; Ishikura H; Westhovens R; Brouwer E; Rojkovich B; Kelly S; den Adel M; Isaacs J; Jacobs H; Gomez-Reino J; Holtkamp GM; Hastings A; Gerlag DM; Tak PP
    Ann Rheum Dis; 2012 Feb; 71(2):180-5. PubMed ID: 21917822
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of ASP2408, a Potent Selective T-Cell Costimulation Modulator After Single and Multiple Ascending Doses in Healthy Volunteers and RA Patients.
    Zhu T; Keirns J; Howieson C; Kaibara A; Goldwater R; Kivitz AJ; Chindalore V; Cohen S; Santos V; Akinlade B; Kernstock R; Delgado-Herrera L; Blahunka PC; Karrer EE; Garg JP; Samberg N; Zeiher BG
    Clin Pharmacol Drug Dev; 2016 Sep; 5(5):408-25. PubMed ID: 27410490
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.